<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83854">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742949</url>
  </required_header>
  <id_info>
    <org_study_id>FPH-TS2012</org_study_id>
    <nct_id>NCT01742949</nct_id>
  </id_info>
  <brief_title>Study to Predict the Benefits of First-line Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence</brief_title>
  <official_title>Evaluation of Advantages Linked to the Use of Humidification by ThermoSmart During Continuous Positive Airway Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fisher and Paykel Healthcare</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the benefits of using first line heated humidification. The
      primary objective of this research is to determine the effect of high levels of
      humidification delivered by ThermoSmart™ on CPAP adherence. In addition, to determine if it
      is possible to predict which patients benefit the most (i.e. be more adherent with therapy)
      from high levels of humidification delivered by ThermoSmart.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence with treatment per night averaged over total time period measured via internal software on the CPAP device and reported using InfoSmart™ software. The report will include all the supporting information recorded within the CPAP device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptance</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acceptance / drop-out rate, leak, ESS score, self-reported nasal symptoms, and functional outcomes of sleep questionnaire score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diagnosed With OSA and Eligible for CPAP Treatment</condition>
  <condition>Naïve to CPAP Therapy</condition>
  <condition>Initial Proscription of a Nasal Mask</condition>
  <arm_group>
    <arm_group_label>Thermosmart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive heated humidification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No humidification</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects use dry CPAP / APAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Heated humidification (ThermoSmart)</intervention_name>
    <arm_group_label>Thermosmart</arm_group_label>
    <arm_group_label>No humidification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years of age

          -  Diagnosed with OSA  and eligible for CPAP treatment under local requirements (AHI&gt;30
             or if AHI is lower than 30, at least 10 micro arousals identified during diagnosis
             PSG).

          -  Naïve to CPAP therapy, i.e have not been prescribed, or used CPAP in the last 5 years

          -  Patients receiving social security coverage (excluding MEAs)

          -  Fluent spoken and written French

        Exclusion Criteria:

          -  Severe heart disease

          -  Co-existing lung disease

          -  Co-existing sleep disorder

          -  Pregnant

          -  Refused participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Pia D'Dortho, MD</last_name>
    <phone>+33 1 40 25 80 80</phone>
    <email>marie-pia.dortho@bch.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pia d'Ortho, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Pia d'Ortho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Schaeffer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Stoïca</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Philippe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carole Philippe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Drouot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Drouot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Maillard</last_name>
      <phone>01 47 60 62 48</phone>
      <email>dominique.maillard@lmr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Maillard</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Najet BOUACH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 10, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
